The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

National Infertility Awareness Week highlights that infertility impacts both men and women, is more prevalent among Black and ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by ...

“The 340B statute does not permit drug companies to unilaterally withhold discounts from 340B hospitals in exchange for the ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Social determinants of health been long understood to influence health outcomes, and this new analysis explores more deeply ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Accessing equitable health care is an ongoing struggle in the US for minority communities due to historical pretexts with new ...